Domainex Limited
Research and experimental development on biotechnology · Pampisford
ActiveUnited KingdomIncorporated 2001Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 412 source facts · 26 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 412 source facts · 26 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 284
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2026-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4315_04336899_20251231
- Source archive
- Accounts_Bulk_Data-2026-09-25.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-12-31
IXBRL · 428 source facts · 39 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 428 source facts · 39 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 326
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2503_04336899_20241231
- Source archive
- Accounts_Monthly_Data-March2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 458 source facts · 38 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 458 source facts · 38 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 354
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2166_04336899_20231231
- Source archive
- Accounts_Monthly_Data-May2024.zip
Accounts to 2022-12-31
IXBRL · 444 source facts · 38 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 444 source facts · 38 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 340
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0026_04336899_20221231
- Source archive
- Accounts_Monthly_Data-September2023.zip
Accounts to 2021-12-31
IXBRL · 452 source facts · 37 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 452 source facts · 37 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 356
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0110_04336899_20211231
- Source archive
- Accounts_Monthly_Data-September2022.zip
Accounts to 2020-12-31
IXBRL · 221 source facts · 26 selected values
Not assessedlegacy record
Accounts to 2020-12-31
IXBRL · 221 source facts · 26 selected values
Not assessed
legacy record
- Reporting period
- 2020-01-01 to 2020-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 159
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0092_04336899_20201231
- Source archive
- Accounts_Monthly_Data-July2021.zip
Accounts to 2019-12-31
IXBRL · 171 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2019-12-31
IXBRL · 171 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2019-01-01 to 2019-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 119
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0080_04336899_20191231
- Source archive
- Accounts_Monthly_Data-July2020.zip
Registered details
04336899- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2001-12-10
- Jurisdiction
- —
- Registered office
- SIGMA BUILDING, 40 SOUTH STREET, PAMPISFORD, CAMBRIDGE, CB22 3FW, ENGLAND
Classification
2 SIC codes7211072190
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
2 SH01-derived rounds2026-06-23
£1,265,715 raised
£9,289,696 estimated post-money
2023-06-26
£30,960 raised
£825,448 estimated post-money
Research and innovation
11 matched grantsInvestigation into polymer lipid particles containing G-protein coupled receptors as a tool to drug discovery and drug detectionBBSRC · Studentship · 2020-10-04 – 2024-10-03 · with 1 other participant£0whole project
Investigation into polymer lipid particles containing G-protein coupled receptors as a tool to drug discovery and drug detection
BBSRC · Studentship · 2020-10-04 – 2024-10-03 · with 1 other participant
£0
whole project
University Of BirminghamleadDomainex Ltd
Development of a novel fragment screening platform for G protein-Coupled ReceptorsLead
Innovate UK · Feasibility Studies · 2018-05-01 – 2019-04-30
£118,317
awarded
Designing a chemical 'toolbox' for the efficient inhibition of metalloenzymesBBSRC · Studentship · 2017-09-30 – 2021-12-31 · with 1 other participant£0whole project
Designing a chemical 'toolbox' for the efficient inhibition of metalloenzymes
BBSRC · Studentship · 2017-09-30 – 2021-12-31 · with 1 other participant
£0
whole project
University of LeedsleadDomainex Ltd
Substrate Peptidomimetic Inhibitors (SPIs) of the COP9 signalosomeEPSRC · Research Grant · 2016-12-01 – 2018-05-30 · with 1 other participant£347,942whole project
Substrate Peptidomimetic Inhibitors (SPIs) of the COP9 signalosome
EPSRC · Research Grant · 2016-12-01 – 2018-05-30 · with 1 other participant
£347,942
whole project
University Of LeicesterleadDomainex Ltd
Integrated computational and synthetic tools to drive the discovery of orthosteric protein-protein interaction inhibitorsEPSRC · Research Grant · 2016-02-01 – 2022-01-31 · with 5 other participants£2,751,526whole project
Integrated computational and synthetic tools to drive the discovery of orthosteric protein-protein interaction inhibitors
EPSRC · Research Grant · 2016-02-01 – 2022-01-31 · with 5 other participants
£2,751,526
whole project
NSD inhibitors for the treatment of multiple myeloma and other cancersLead
Innovate UK · Feasibility Studies · 2015-10-01 – 2016-12-31
£139,883
awarded
Development of a new treatment for Chronic Obstructive Pulmonary DiseaseLead
Innovate UK · Collaborative R&D · 2014-10-01 – 2017-09-30
£1,215,100
awarded
Proving the feasibility of using SMYD3 inhibitors as therapeutics for treatment of hepatocellular carcinoma and other cancers.Lead
Innovate UK · Feasibility Studies · 2013-02-01 – 2014-01-31
£150,000
awarded
Proving the feasibility of IKKe inhibitors as therapeutics for treatment of Chronic Obstructive Pulmonary Disease (COPD)Lead
Innovate UK · Feasibility Studies · 2012-10-01 – 2014-01-31
£150,000
awarded
A new drug targeting the enzymes TBK1 and IKKe for the treatment of cancerLead
Innovate UK · GRD Development of Prototype · 2011-11-01 – 2013-01-31
£250,000
awarded
Novel assays and platforms for testing and controlling regenerative medicine productsLeadInnovate UK · Feasibility Studies · 2010-08-01 – 2011-03-31 · with 1 other participant£102,060awarded
Novel assays and platforms for testing and controlling regenerative medicine productsLead
Innovate UK · Feasibility Studies · 2010-08-01 – 2011-03-31 · with 1 other participant
£102,060
awarded
Domainex Limitedlead£102,060